Company Overview and News
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY
KUALA LUMPUR (Oct 2): theedgemarkets.com highlighted twelve stocks with momentum at Bursa Malaysia’s afternoon market close today. All stocks displayed negative momentum.
7108 0162 BSMAF 5256 1818
KUALA LUMPUR, Oct 2 — Bursa Malaysia ended the morning session in positive territory, boosted by feel-good market sentiment after the US and Canada inked an agreement to revise their trade pact, dealers said.
PBLOF 7108 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF
KUALA LUMPUR: Upstream activities are increasing in tandem with crude oil prices that are climbing steadily. While things are looking up in the oil and gas (O&G) industry, many domestic O&G companies are still bogged down by high borrowings and finance costs.
5115 BRDBF 7108 BSMAF 5255 5210 1818
KUALA LUMPUR (Aug 29): Perdana Petroleum Bhd said its wholly-owned subsidiary Petra Offshore Limited (POL) and Nam Cheong International Ltd (NCIL) have come to a settlement in their dispute relating to a memorandum of agreement (MoA).
7108 BSMAF 1818
KUALA LUMPUR (Aug 24): After five straight quarters of losses, Perdana Petroleum Bhd was back in the black with a net profit of RM10.09 million for the second quarter ended June 30, 2018.
KUALA LUMPUR (July 5): Hong Leong Investment Bank Bhd has downgraded its recommendation on Dayang Enterprise Holdings Bhd to Hold (from Buy), and reduced its share target price to 63 sen from 67 sen previously, for lower offshore support vessels (OSV) valuations, in line with industry peers, pending a clear restructuring plan.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...